BCIQ Profiles

Company Profile Report
0623 ECP Abata EMB 7AM ET
BioCentury & Getty Images

Emerging Company Profile

Abata: engineering targeted Treg cell therapies with TCRs

Emerging Company Profile: Third Rock launches Abata with $95M series A to develop targeted Treg cell therapies for autoimmune disorders

Third Rock launches Abata with a $95 million series A to develop targeted Treg cell therapies for autoimmune disorders, starting with progressive MS. 

Jun 23, 2021 | 11:20 AM GMT

Read the full 667 word article

How to gain access

Continue reading with a
two-week free trial.